Blog Posts
April 6, 2021

LARVOL to be Featured at ScaleUp 360° Competitive Intelligence in Pharma & Life Science Virtual Conference

Blog Posts
April 6, 2021

LARVOL to be Featured at ScaleUp 360° Competitive Intelligence in Pharma & Life Science Virtual Conference

Author

LARVOL, leading provider of data and intelligence solutions for the pharmaceutical and biotech industry, will be featured at the ScaleUp 360° Competitive Intelligence in Pharma & Life Science virtual conference. ScaleUp 360° brings together the industries' top decision makers in pharma and life science working on competitive and market intelligence tools and strategies.

San Francisco, CA (April 6, 2021) – BUSINESS WIRELARVOL, leading provider of data and intelligence solutions for the pharmaceutical and biotech industry, will be featured at the ScaleUp 360° Competitive Intelligence in Pharma & Life Science virtual conference. ScaleUp 360° brings together the industries' top decision makers in pharma and life science working on competitive and market intelligence tools and strategies.

LARVOL will use the event to rollout the launch of their proprietary tool for pharma social listening, VIEW. VIEW is the first social listening and sentiment analysis platform focused on Twitter-verified oncologists, researchers, and Digital Opinion Leaders (DOLs). LARVOL’s team of MDs and PhDs collates data from over 25,000 sources and distills the most relevant findings into concise reports that provide real-time insights and time-saving analysis. Access to this curated information will enable pharma CI teams to make informed, up-to-the-minute decisions influencing their oncology drug positioning.

“By now, most pharma CI teams understand that social listening is a must-have piece of their competitive intelligence strategy,” said LARVOL Head of Operations, Sabrina Bellisario. “But implementation remains a grey area. To truly benefit from the wealth of information social listening presents, CI teams need a clearer picture of what success looks like and what tools and strategies can help them get the data they need to bring product to market.”  

“There’s a significant void in the market for tools tailored to the social listening needs of pharma,” Bellisario continues. “VIEW answers that need with an intuitive, easy-to-use solution for CI teams looking to cut through the white noise and tap into the immediate news, trending discussions and, more importantly, the sentiment of DOL’s reactions to immediately influence their product development and go-to market strategies.”  

For more information visit LARVOL.com.

About LARVOL:

LARVOL supports the data and intelligence needs of the pharmaceutical and biotech industry with expert curated information. Their products include competitive intelligence, KOL monitoring, and social listening tools along with predictive cancer biomarker and clinical trial databases. LARVOL curates data using a proven combination of broad therapeutic-area expertise and proprietary natural language processing technology to keep their customers at the forefront of the industry. The VR-first, remote-always LARVOL team includes MDs, PhDs, and industry professionals around the globe who curate data from over 25,000 sources and distill the most relevant information into concise reports that provide real-time insights and time-saving analysis.

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.